ResearcherRuijin HospitalActive in the last 2 years

Baiyong Shen

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: ClinicalTrials.gov.

Their work

Papers: 0
Trials: 4 (principal investigator on 3)
Grants: 0
Labs led: 0
Collaborators: 1

Papers, trials and grants by year

2020: 1 trial · 2021: none · 2022: none · 2023: none · 2024: 2 trials · 2025: none · 2026: 1 trial

Trials 4

A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer Study director NCT07649928 ↗
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC Principal investigator NCT06573398 ↗
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors Principal investigator NCT06577532 ↗
Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors Principal investigator NCT04400357 ↗

Closest collaborators

The 1 strongest of 1 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jiabin Jin · 1 shared trial, 2024 · strength 0.68
- Trial Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC NCT06573398 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.